- Title: Subtitle
- Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial
- Creators
- Richard D. Carvajal - Memorial Sloan Kettering Cancer CenterMark Agulnik - Northwestern UniversityChristopher W. Ryan - Oregon Health & Science UniversityMohammed M. Milhem - University of IowaSuzanne George - Dana-Farber Cancer InstituteRobin Lewis Jones - Seattle Cancer Care AllianceBartosz Chmielowski - University of California, Los AngelesBrian Andrew Van Tine - Washington University in St. LouisHussein Abdul-Hassan Tawbi - UPMC Hillman Cancer CenterAnthony D. Elias - University of Colorado Cancer CenterWilliam L. Read - Emory UniversityG. Thomas Budd - Cleveland ClinicJoe Hirman - Pacific Northwest Research StationPaul Weiden - Biopharma Consulting Services, Seattle, WACathryn M. Bennett - Mabvax TherapeuticsPhilip O. Livingston - Mabvax TherapeuticsDavid Hansen - Mabvax TherapeuticsRobert G. Maki - Icahn School of Medicine at Mount SinaiGary K. Schwartz - Columbia University Irving Medical CenterRashmi Chugh - University of Michigan–Ann Arbor
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.32(15_suppl), pp.10520-10520
- DOI
- 10.1200/jco.2014.32.15_suppl.10520
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2014
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363313602771
Abstract
Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial
Journal of clinical oncology, Vol.32(15_suppl), pp.10520-10520
05/20/2014
DOI: 10.1200/jco.2014.32.15_suppl.10520
Details
Metrics
5 Record Views